Understand the source comparison
Best Peptides for Meniscus Recovery: Research-Supported Comparison
Before selecting a peptide protocol, understand what each compound does at the molecular level and how those mechanisms apply to fibrocartilage structure. BPC-157 VEGF upregulation, angiogenesis Extends vascular penetration into red-white zone, supports fibrob
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting a peptide protocol, understand what each compound does at the molecular level and how those mechanisms apply to fibrocartilage structure.
- BPC-157
- VEGF upregulation, angiogenesis
- Extends vascular penetration into red-white zone, supports fibroblast survival
- 200–500 mcg daily, 14–21 days
- Subcutaneous peri-articular or intra-articular
- Moderate. Animal models show dose-dependent vascular density increase
- TB-500 (Thymosin Beta-4)
- Actin sequestration, cell migration
- Accelerates fibroblast recruitment to injury site, increases collagen Type I synthesis
- 2–5 mg twice weekly, 3–4 weeks
- Subcutaneous or intramuscular
- Moderate. Demonstrated in tendon and ligament models, limited meniscus-specific trials
- GHK-Cu
- Lysyl oxidase activation, collagen crosslinking
- Stabilizes collagen matrix, improves tensile strength in remodeling tissue
- 1–3 mg daily, weeks 2–6 post-injury
- Subcutaneous
- Low. Strong evidence in dermal wound healing, extrapolated to fibrocartilage
- IGF-1 LR3
- IGF-1 receptor agonism, anabolic signaling
- Stimulates chondrocyte-like cell proliferation, proteoglycan synthesis
- 40–80 mcg daily, 2–3 weeks
- Low. Targets hyaline cartilage pathways more than fibrocartilage
- GHRP-6 + CJC-1295 (GH secretagogues)
- Pulsatile GH/IGF-1 elevation
- Systemic anabolic environment, general tissue repair support
- GHRP-6: 100 mcg 3×/day; CJC-1295: 2 mg weekly
- Very Low. Indirect mechanism, no fibrocartilage-specific data